The company's innovative product pipeline and exclusive CanSEEK technology offer groundbreaking cancer treatments that address unmet clinical needs, positioning POINT for leadership in the biopharma ...

大型3期临床试验已经证明，对于局部晚期或转移性前列腺癌患者来说，在长期雄激素剥夺疗法（ADT）的基础上加用放射治疗能够带来显著的生存获益。因此，放疗是这类患者的有效选择之一。然而，部分患者可能会出现尿路梗阻症状，比如排尿困难、残余尿量增多等；在这种情况下，我认为根治性前列腺切除术可能比放疗更为有利。

"North America accounts for the largest share of the global Radioligand Therapy (RLT) market in 2024, driven by its advanced healthcare infrastructure, high adoption of innovative oncology treatments, ...

Novartis' experimental Lu-PSMA-617 radioligand therapy has improved the survival of prostate cancer patients with a hard-to-treat form of the disease, the Swiss drugmaker said on Tuesday. ZURICH, ...

Swiss pharma giant Novartis NVS entered a global research collaboration with Artios Pharma Limited, a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for ...

Orano Med, a subsidiary of the Orano Group specializing in nuclear medicine, announced today that its long-standing collaboration with the multinational pharmaceutical company Roche (SIX: RO, ROG; ...

The MarketWatch News Department was not involved in the creation of this content. DELRAY BEACH, Fla., Sept. 13, 2025 /PRNewswire/ -- The global Radioligand Therapy (RLT) Market, valued at US$2.36 ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (CLVT) (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch report, ...

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison ZURICH (Reuters) - Novartis' experimental Lu-PSMA-617 radioligand therapy has ...

Novartis (Switzerland) is a global pharmaceutical leader and one of the pioneers in advancing radioligand therapy (RLT). The company has played a pivotal role in shaping this therapeutic area by ...

DELRAY BEACH, Fla., Sept. 13, 2025 /PRNewswire/ -- The global Radioligand Therapy (RLT) Market, valued at US$2.36 billion in 2024, stood at US$3.15 billion in 2025 and is projected to advance ...